From: | Becker's Supply Chain Report <editorial@beckershealthcare.com> |
Subject: | Senators deem Mylan's generic EpiPen a temporary solution | MD Anderson points to Epic implementation for 77% drop in adjusted income | The rise of the unbranded drug ad | Roche's Zika test earns FDA emergency use authorization |
Preheader: | |
Reply: | editorial@beckershealthcare.com |
|